Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma

Many chemotherapeutic regimens will induce remission in dogs with lymphoma, but almost all dogs suffer relapse. Mitoxantrone was selected for evaluation as single‐agent chemotherapy for relapsing canine lymphoma based on its use in humans undergoing salvage chemotherapy for non‐Hodgkin's lympho...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of veterinary internal medicine Vol. 12; no. 5; pp. 325 - 329
Main Authors:	Lucroy, M.D, Phillips, B.S, Kraegel, S.A, Simonson, E.R, Madewell, B.R
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01-09-1998
Subjects:	adverse effects Animals antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use B-lymphocytes Clinical trial Dog Dog Diseases - drug therapy Dogs drug therapy Infusions, Intravenous lymphoma Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - veterinary Lymphoma, T-Cell - drug therapy Lymphoma, T-Cell - veterinary Malignancy Mitoxantrone - administration & dosage Mitoxantrone - therapeutic use relapse Remission T-lymphocytes Treatment Outcome Veterinary
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Many chemotherapeutic regimens will induce remission in dogs with lymphoma, but almost all dogs suffer relapse. Mitoxantrone was selected for evaluation as single‐agent chemotherapy for relapsing canine lymphoma based on its use in humans undergoing salvage chemotherapy for non‐Hodgkin's lymphoma and its tumoricidal effect against canine lymphoma. Dogs entered into study had multicentric lymphoma, and all had been treated solely with a standard combination chemotherapy protocol. At 1st relapse, all dogs were again staged and underwent lymph node biopsy. Mitoxantrone was administered IV at 6 mg/m2 every 21 days. Dogs were evaluated for lymphadenopathy before each dose of mitoxantrone. Fifteen dogs were entered into study. The average age (±SEM) of the dogs studied was 7.7 ± 0.91 years, and most dogs were large (mean ± SEM weight, 24.44 ± 2.15 kg). Twelve dogs (80%) had B‐cell lymphoma, and 3 had T‐cell lymphoma. Dogs were staged IV (n = 12) or V (n = 3). The median duration of chemotherapy before entry into the study was 98 days. Overall median duration of response after mitoxantrone chemotherapy was 21 days. Complete responses were attained in 7 of 15 dogs (47%) with a median response duration of 84 days. Nine of 15 (60%) dogs attained a complete remission with additional chemotherapy after failing mitoxantrone chemotherapy. Mild toxicities were observed after mitoxantrone administration. No adverse reactions were observed during mitoxantrone infusions. The results of this study demonstrate that mitoxantrone, as a single agent, has limited value for dogs with lymphoma at 1st relapse after conventional multidrug chemotherapy.
Bibliography:	istex:B7DE56FEEBE146E3EAA1478EFF2E7C2150A76304 ArticleID:JVIM325 ark:/67375/WNG-JXLQ9SXG-M ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0891-6640 1939-1676
DOI:	10.1111/j.1939-1676.1998.tb02130.x